Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

Company Announces Corporate Restructuring to Focus on Strategic Alliances

and M&A

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN), a company developing innovative therapeutics for the treatment of viral infections and cancer, today provided an update on its ongoing development programs. The company also announced that it will initiate a corporate restructuring that will extend the company's financial resources to pursue near-term corporate development opportunities, sale of specific programs, M&A and alternative financial arrangements to maximize the value of its assets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are committed to the continued advancement of HspE7, Hsp 6/11 and Poly-ICR, and as such, we are making difficult yet necessary decisions today to ensure these products have every opportunity to succeed," said Gregory M. McKee, president and chief executive officer at Nventa. "As part of our commitment to the continued advancement of HspE7, Hsp 6/11 and Poly-ICR, we are aggressively seeking strategic alliances, including merger and acquisition opportunities, which will allow us to realize the greatest value for each of these important programs."

HspE7: Lead Product Candidate for the Treatment of Cervical Intraepithelial Neoplasia (CIN)

A recently completed Phase 1 clinical trial of HspE7, a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), demonstrated an excellent safety profile, while providing compelling data to support HspE7's immunologic activity. Based on the positive Phase 1 trial results, the next planned initiatives include Phase 2 clinical studies that will evaluate HspE7 as a potential treatment for both low-grade cervical dysplasia (CIN 1
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mich. Every day, their baby stopped breathing, his ... his lungs. April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good ... Gionfriddo, about her now 20-month-old son, Kaiba. "At that ... would take it and run with it." , They ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
(Date:5/23/2013)... N.Y. , May 23, 2013  BioScrip, Inc. ... Company will present at the Jefferies 2013 Global Healthcare ... Grand Hyatt New York. Richard ... Hai Tran , Chief Financial Officer, ... a.m. Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... and fight Human Immunodeficiency Virus (HIV) infections, today announced ... 30, 2011. GeoVax reported a net loss ... ended September 30, 2011, compared to $644,666 ($0.04 per ...
... Theravalues, a Japan based bio-venture, announced today ... prevention of heart failure and its progression for the ... started with the registration in July 2010, conducted by ... and University of Shizuoka, Japan, the researchers found that ...
... Research has expanded its research footprint to support ... offering high-quality biospecimens coupled with unprecedented premium data ... with AdeptBio, LLC ( http://www.adeptbio.com ).   ... services as needed to facilitate prospective collections of ...
Cached Biology Technology:GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients 2ACORN Research, LLC Announces Partnership with AdeptBio, LLC 2
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... DC Cancer researchers at Georgetown University,s Lombardi Comprehensive ... they say shuts down growth of human glioblastoma tumors ... of brain cancers; there is no effective treatment. In ... researchers demonstrate how this antibody latches onto a receptor ...
... joined forces in a groundbreaking assessment of the status of ... fishery ecosystem scientist from the CSIRO Wealth from Oceans Flagship, ... report on a two-year study, led by US scientists Dr ... the University of Washington. The study shows that steps ...
... A new approach to windows that could let in ... to 99% in buildings in Tropical regions without losing ... the International Journal of Engineering Systems Modelling and ... in the School of Environment, Resources and Development, at ...
Cached Biology News:Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 2Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 3Global curbs on overfishing are beginning to work 2Opening a new window on daylight 2
with GlutaMAXIL-glutamine...
Request Info...
... peptide derived from the C terminal region ... This peptide sequence is downstream from the ... Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin 36-transfected ...
Request Info...
Biology Products: